Data / Form D filings / Ollin Biosciences, Inc.
Ollin Biosciences, Inc.: Form D filing
Ollin Biosciences, Inc., a biotechnology company in Austin, TX, filed a Form D with the SEC in 2026. The latest, on June 24, 2026, reports $156.2 million sold of a $330 million offering to 32 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 1250 S. CAPITAL OF TEXAS HWY BUILDING 3, SUITE 400, Austin, TX, 78746
- Phone
- (512) 885-4957
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2022
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 2141184
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jun 24, 2026 | New notice | $330,000,000 | $156,249,990 | $173,750,010 | 32 | May 14, 2026 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Jason Ehrlich | Executive Officer, Director | |
| Paul Berns | Director | |
| Jason Coloma | Director | |
| Cariad Chester | Director | |
| Fred Cohen | Director | |
| Alaa Halawa | Director | |
| Travis Murdoch | Director |
Other biotechnology companies in Texas that filed recently
- Nuclein, LLC $15.7 million · Oct 27, 2026
- OncoNano Medicine, Inc. $10.1 million · Oct 8, 2026
- Solaris Endovascular Inc. $5 million · Oct 1, 2026
- Hera Biotech, Inc. $1.7 million · Sep 23, 2026
- Kayak Therapeutics, Inc. $25 million · Aug 21, 2026
- InnovoTEX Inc. $2.7 million · Aug 18, 2026
Every Form D from the week of Jun 22, 2026 · All recent filings in Texas · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Ollin Biosciences, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.